Sanofi Says FDA Extends Review Target Date For Tolebrutinib
RefinitivMenos de 1 minuto de leitura
Sanofi SA 
SAN:
FDA EXTENDS REVIEW TARGET DATE FOR TOLEBRUTINIB
FDA DECISION DATE FOR TOLEBRUTINIB SET FOR DECEMBER 28, 2025
FDA CONSIDERS ADDITIONAL ANALYSES A MAJOR AMENDMENT TO NDA
Entrar ou criar uma conta gratuita para ler essa notícia